Figure 2.
Characterization of GSK2831781, an affinity‐enhanced and ADCC‐enhanced afucosylated IgG1 LAG‐3‐specific mAb. Fold change in the proliferation of CD4+ antigen‐specific T cells in the presence of GSK2831781 alone and with anti‐CD16, relative to untreated antigen stimulation controls. ADCC, antibody‐dependent cellular cytotoxicity; IgG1, immunoglobulin G1; mAb, monoclonal antibody; PBMC, peripheral blood mononuclear cell.